# A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

> **NCT02038764** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 37 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Placebo
- **BIOLOGICAL:** PF-06342674 Dose A
- **BIOLOGICAL:** PF-06342674 Dose B
- **BIOLOGICAL:** PF-06342674 Dose C
- **BIOLOGICAL:** PF-06342674 Dose D

## Key facts

- **NCT ID:** NCT02038764
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-04
- **Primary completion:** 2016-09-13
- **Final completion:** 2016-09-13
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2018-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02038764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02038764, "A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02038764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*